Developer docs
API playgroundTry for free, no card

Search company profiles

Windham Venture Partners

Full company profile

uuid00062zw

Namestring
Windham Venture Partners
Websiteurl
windhamvp.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Windham Venture Partners is a New York City-based venture capital firm founded in 2006 that invests exclusively in healthcare technology companies. Operating under the tagline 'Investing in life-saving, game-changing HealthTech,' the firm provides capital investment to HealthTech startups at various stages alongside strategic guidance drawn from deep healthcare domain expertise. Its business model is that of a specialized boutique VC: deploying and managing limited-partner capital into a portfolio of HealthTech companies and earning revenue via traditional fund economics (management fees and carried interest on portfolio realizations). The firm does not sell a product or service to end customers; its commercial interface is with institutional limited partners via a dedicated LP Login portal and newsletter communications, and with portfolio companies via capital deployment and board-level support.

The firm is led by co-founders Adam Fine (General Partner & CEO) and Roger Fine (Chairman, who concurrently chairs the Robert Wood Johnson Foundation), with David Kereiakes as Managing Partner and Lorne Taichman as Director of Science & Technology. The team is intentionally small (1-10 employees), reflecting a focused thesis rather than a generalist multi-stage platform. The firm maintains dual branding across 'Windham Venture Partners' (windhamvp.com) and 'Windham Capital Partners' (windhamcap.com), suggesting either a legacy rebrand or coexisting entity structures. Operationally the firm appears active based on maintained website infrastructure (Portfolio, News, About, Team, Contact pages plus LP portal), but the source data does not disclose fund sizes, AUM, portfolio company names, or recent investment activity.

Short descriptiontext

Windham Venture Partners is a New York-based venture capital firm founded in 2006 that invests exclusively in healthcare technology companies, providing capital and strategic guidance to HealthTech startups. The firm serves institutional limited partners via a dedicated LP portal.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital, healthcare technology investing, healthtech venture funding, early-stage healthcare investment, life sciences capital
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Funds, Trusts, and Other Financial Vehicles525
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Windham Venture Partners is a New York City-based venture capital firm founded in 2006 that invests in life-saving and game-changing HealthTech companies. The firm manages capital on behalf of limited partners and deploys it into early-stage and growth-stage healthcare technology ventures, while providing strategic guidance and sector expertise to portfolio companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Windham Venture Partners is a venture capital firm focused on HealthTech investments. The company does not offer a product or service offering in the traditional SaaS sense; rather, it operates as an investment firm managing a portfolio of health technology companies. The source does not identify named products or services beyond the general venture investment operations.

Product and service1 record
1HealthTech Venture Capital Investing
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Long-tenured venture firm investing in early-stage life sciences, healthcare, and technology companies. Directly comparable as a healthcare/specialist VC with a similarly longstanding track record.

TypeDirect peer
Description

Healthcare-dedicated investment firm covering therapeutics, medical devices, and digital health. Direct vertical peer to Windham in dedicated HealthTech focus and stage orientation.

TypeDirect peer
Description

Large multi-stage VC with one of the most active healthcare investing franchises globally. Comparable for healthcare sector specialization, though with materially larger fund and team scale.

TypeDirect peer
Description

Early-stage venture firm with deep healthcare and technology roots dating back decades. Directly comparable as a sector-focused firm with healthcare specialization.

TypeDirect peer
Description

Early-stage venture firm focused exclusively on life sciences, including therapeutics, medical devices, and platform technologies. Direct peer in healthcare-only venture investing.

TypeDirect peer
Description

Multi-stage venture firm with significant healthcare and technology investing practice. Comparable for stage range and sector breadth within healthcare.

TypeDirect peer
Description

Early-stage venture firm with substantial healthcare and biotech investment activity alongside tech investing. Comparable for healthcare sector exposure and early-stage orientation.

TypeBroad incumbent
Description

Large generalist VC with a dedicated Bio/Health fund actively investing across healthcare stages. Broad incumbent that competes for the same HealthTech deal flow with materially more capital.

TypeBroad incumbent
Description

Large venture arm of Alphabet investing across stages and sectors, including a notable healthcare/life sciences practice. Broad incumbent competing in HealthTech with substantially larger fund size.

TypeDirect peer
Description

Crossover fund manager with deep healthcare and biotech specialization. Directly comparable for healthcare investment focus, though operating as a crossover/hybrid model rather than traditional early-stage VC.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment64 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Windham Venture Partners

Healthcare Venture Capitalwindhamvp.com

Windham Venture Partners is a New York-based venture capital firm founded in 2006 that invests exclusively in healthcare technology companies, providing capital and strategic guidance to HealthTech startups. The firm serves institutional limited partners via a dedicated LP portal.

What Windham Venture Partners does

Windham Venture Partners is a New York City-based venture capital firm founded in 2006 that invests exclusively in healthcare technology companies. Operating under the tagline 'Investing in life-saving, game-changing HealthTech,' the firm provides capital investment to HealthTech startups at various stages alongside strategic guidance drawn from deep healthcare domain expertise. Its business model is that of a specialized boutique VC: deploying and managing limited-partner capital into a portfolio of HealthTech companies and earning revenue via traditional fund economics (management fees and carried interest on portfolio realizations). The firm does not sell a product or service to end customers; its commercial interface is with institutional limited partners via a dedicated LP Login portal and newsletter communications, and with portfolio companies via capital deployment and board-level support.

The firm is led by co-founders Adam Fine (General Partner & CEO) and Roger Fine (Chairman, who concurrently chairs the Robert Wood Johnson Foundation), with David Kereiakes as Managing Partner and Lorne Taichman as Director of Science & Technology. The team is intentionally small (1-10 employees), reflecting a focused thesis rather than a generalist multi-stage platform. The firm maintains dual branding across 'Windham Venture Partners' (windhamvp.com) and 'Windham Capital Partners' (windhamcap.com), suggesting either a legacy rebrand or coexisting entity structures. Operationally the firm appears active based on maintained website infrastructure (Portfolio, News, About, Team, Contact pages plus LP portal), but the source data does not disclose fund sizes, AUM, portfolio company names, or recent investment activity.

Windham Venture Partners firmographics

Firmographics
Name
Windham Venture Partners
Website
https://windhamvp.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Windham Venture Partners is a New York-based venture capital firm founded in 2006 that invests exclusively in healthcare technology companies, providing capital and strategic guidance to HealthTech startups. The firm serves institutional limited partners via a dedicated LP portal.
Ownership category
akta.pro rank

Windham Venture Partners industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (52394), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital
  • Healthcare technology investing
  • Healthtech venture funding
  • Early-stage healthcare investment
  • Life sciences capital

Where Windham Venture Partners is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Windham Venture Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations

Distribution channels1 record

Marketing channels1 record

Windham Venture Partners product offering

Product offering

Core offering

Windham Venture Partners is a New York City-based venture capital firm founded in 2006 that invests in life-saving and game-changing HealthTech companies. The firm manages capital on behalf of limited partners and deploys it into early-stage and growth-stage healthcare technology ventures, while providing strategic guidance and sector expertise to portfolio companies.

Product overview

Windham Venture Partners is a venture capital firm focused on HealthTech investments. The company does not offer a product or service offering in the traditional SaaS sense; rather, it operates as an investment firm managing a portfolio of health technology companies. The source does not identify named products or services beyond the general venture investment operations.

Differentiator

Problem solved

Functional benefit

Products and services

  • HealthTech Venture Capital Investing

Companies that use Windham Venture Partners

Customer profile

Ideal customer profiles2 records

Windham Venture Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Windham Venture Partners partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Windham Venture Partners competitors and assessment

Company assessment

Direct peers

  • ARCH Venture Partners: Long-tenured venture firm investing in early-stage life sciences, healthcare, and technology companies. Directly comparable as a healthcare/specialist VC with a similarly longstanding track record.
  • OrbiMed: Healthcare-dedicated investment firm covering therapeutics, medical devices, and digital health. Direct vertical peer to Windham in dedicated HealthTech focus and stage orientation.
  • New Enterprise Associates (NEA): Large multi-stage VC with one of the most active healthcare investing franchises globally. Comparable for healthcare sector specialization, though with materially larger fund and team scale.
  • Venrock: Early-stage venture firm with deep healthcare and technology roots dating back decades. Directly comparable as a sector-focused firm with healthcare specialization.
  • 5AM Ventures: Early-stage venture firm focused exclusively on life sciences, including therapeutics, medical devices, and platform technologies. Direct peer in healthcare-only venture investing.
  • Polaris Partners: Multi-stage venture firm with significant healthcare and technology investing practice. Comparable for stage range and sector breadth within healthcare.
  • Khosla Ventures: Early-stage venture firm with substantial healthcare and biotech investment activity alongside tech investing. Comparable for healthcare sector exposure and early-stage orientation.
  • RA Capital Management: Crossover fund manager with deep healthcare and biotech specialization. Directly comparable for healthcare investment focus, though operating as a crossover/hybrid model rather than traditional early-stage VC.

Broad incumbents

  • Andreessen Horowitz (a16z) Bio/Health: Large generalist VC with a dedicated Bio/Health fund actively investing across healthcare stages. Broad incumbent that competes for the same HealthTech deal flow with materially more capital.
  • GV (Google Ventures): Large venture arm of Alphabet investing across stages and sectors, including a notable healthcare/life sciences practice. Broad incumbent competing in HealthTech with substantially larger fund size.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Windham Venture Partners social profiles

Digital presence

Windham Venture Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Windham Venture Partners leadership team

Management profile

Number of profiles

Profiles4 records

Windham Venture Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Windham Venture Partners M&A and investment

M&A and investment

M&A

Investments64 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Windham Venture Partners

What does Windham Venture Partners do?

Windham Venture Partners is a New York City-based venture capital firm founded in 2006 that invests in life-saving and game-changing HealthTech companies. The firm manages capital on behalf of limited partners and deploys it into early-stage and growth-stage healthcare technology ventures, while providing strategic guidance and sector expertise to portfolio companies.

Is Windham Venture Partners a public or private company?

Windham Venture Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Windham Venture Partners founded?

Windham Venture Partners was founded in 2006. It employs 11 to 50 people.

Where is Windham Venture Partners based?

Windham Venture Partners is headquartered in New York, United States, in the North America region.

Who are Windham Venture Partners's main competitors?

Direct peers on record are ARCH Venture Partners, OrbiMed, New Enterprise Associates (NEA), Venrock, 5AM Ventures, Polaris Partners, Khosla Ventures and RA Capital Management. Broad incumbents are Andreessen Horowitz (a16z) Bio/Health and GV (Google Ventures).

Does Windham Venture Partners have an API?

No public API is recorded for Windham Venture Partners.

What industry is Windham Venture Partners in?

Windham Venture Partners's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireWindham Venture Partners Hires Successful Healthcare Investor, David Kereiakes, And Expands Presence in the MidwestWindham Venture Partners, a New York-based healthtech venture capital firm, announced the appointment of David Kereiakes as Managing Partner to lead its newly established Cincinnati office, marking the firm's strategic expansion into the Midwest. Kereiakes brings over a decade of healthcare investing experience, having helped healthcare entrepreneurs realize more than $1 billion in value and leading over $250 million in private placements across roles at Providence Ventures and RC Capital. The move targets underserved Midwestern innovation hubs, as the region receives less than 5% of total VC funding despite being large and populous.socaltech.comChromaCode Snags $10M In Series CChromaCode, a Carlsbad-based molecular testing equipment developer, raised $10M in a Series C extension round from Adjuvant Capital. The company has now raised $38M in the round, and the funds will support global expansion and development of its high-definition PCR platform.PR NewswireCredSimple Secures $14 Million in Series B Financing led by Questa CapitalCredSimple, a cloud-based healthcare credential verification organization, announced the closing of a $14 million Series B financing round led by Questa Capital, with participation from existing investors Windham Venture Partners and Primary Ventures. The company will use the funds to enhance customer experience with new products and services, accelerate sales, and expand its management team. CredSimple's Credential Verification Cloud platform automates and streamlines provider credentialing for healthcare organizations including health plans, telehealth companies, and physician associations.FinSMEsNovellusDx Completes $6M Equity FinancingNovellusDx, a Jerusalem-based functional genomics company, completed a $6M equity financing. Backers include Helsinn Investment Fund, Bio Capital Impact Fund, and Windham Venture Partners, adding to nearly $17M raised. The company will use the funds to accelerate commercialization and support R&D.FinSMEsVytronUS Raises $49M in Series C FinancingVytronUS, a Sunnyvale-based medical device company, raised $49 million in Series C financing from Apple Tree Partners, NEA, BioStar Ventures, and Windham Venture Partners. The company will use the funds for technology refinements and clinical trials of its Low-Intensity Collimated Ultrasound Cardiac Mapping & Ablation System for atrial fibrillation and other arrhythmias.PE HubPGDx scores $21.4 mln Series ABaltimore-based PGDx raised $21.4 million in Series A funding led by New Enterprise Associates, with participation from Windham Venture Partners and Nanjing Kaiyuan Growth Capital. Dr. Justin Klein joined the board, while Felix Dawson and Adam Fine became observers.FinSMEsPersonal Genome Diagnostics Raised $21.4M in Series A FundingPersonal Genome Diagnostics raised $21.4 million in a Series A round led by New Enterprise Associates, with participation from Windham Venture Partners and Nanjing Kaiyuan Growth Capital. The funds will support expanding operations and adoption of its cancer genome testing services. The company, founded in 2010, has 63 employees and a CLIA-certified laboratory.PR NewswirePersonal Genome Diagnostics Secures $21.4 Million in Series A Financing Led By New Enterprise AssociatesPersonal Genome Diagnostics raised $21.4 million in Series A financing led by New Enterprise Associates. The company, founded in 2010, provides cancer genome testing and plans to expand from 11,000 to 25,000 square feet in 2016.SiliconANGLEHealthcare group messaging app provider Cureatr raises $13m Series B - SiliconANGLECureatr raised $13 million in a Series B led by Deerfield Investments, with participation from Cerner Capital and Windham Ventures. The healthcare messaging app will use the funds to launch networks in new markets and expand partnerships. The company has raised $19.1 million to date.FinSMEsCoravin Secures $13.6M in Series C-1 Financing - FinSMEsCoravin Inc. secured $13.6 million in Series C-1 financing led by Windham Venture Partners, with participation from Quadrille Capital. The company, which has raised over $39 million to date, will use the funds for research and development, market expansion, and channel penetration. The device allows accessing wine without pulling the cork.